Crevas 5/10/20/40 Mg 5/10/20/40 mg Tablet
PDF Leaflet Revision Date: 27 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
To reduce cardiovascular risk and treat hypercholesterolaemia.
Dosage (summary)
5-40 mg orally once daily; starting dose typically 5 mg.
Onset of Action / Duration
Onset: 1 week, Duration: 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
- Asian ancestry
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Ciclosporin
- Gemfibrozil
- Protease inhibitors
- Niacin
Contraindications
- Hypersensitivity to rosuvastatin
- Active liver disease
- Severe renal impairment
- Pregnancy and lactation
- Myopathy
Common side effects
- Myalgia
- Constipation
- Nausea
- Headache
- Dizziness
Counselling Points
- Report unexplained muscle pain or weakness
- Monitor liver function tests
- Avoid alcohol consumption
Serious warnings
- Risk of myopathy and rhabdomyolysis
- Liver function monitoring required
- Caution in renal impairment
Important Disclaimer
The Crevas 5/10/20/40 Mg 5/10/20/40 mg Tablet professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
